Preclinical Development of SHR-1819, a Potent Humanized IL-4Rα Antibody for Treating Type 2 Inflammatory Diseases
The results supported SHR-1819 as a promising preclinical candidate for the treatment of type 2 inflammatory diseases, including asthma, AD and AR.
Authors
- Guolin Zhao (ORCID: https://orcid.org/0000-0002-0002-0293)
- Kaili Liu (ORCID: https://orcid.org/0000-0001-7700-4075)
- Cheng Liao (ORCID: https://orcid.org/0000-0003-2974-2158)
- Zhijun Wang (ORCID: https://orcid.org/0009-0003-0835-8736)
- Changyong Yang
- Yuan Lin (ORCID: https://orcid.org/0000-0001-5449-3435)
- Jun Zhang (ORCID: https://orcid.org/0000-0002-5843-8705)
- Zhou Tang
Institutions
- Fosun Pharma (China) (CN)
- Jiangsu Hengrui Medicine (China) (CN)
Publication Details
- Journal
- Journal of Inflammation Research
- Published
- 2024-09-01
- DOI
- https://doi.org/10.2147/jir.s471963
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.33